Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Level of Maternal Antibody Required to Protect Neonates against Early-Onset Disease Caused by Group B Streptococcus Type la: A Multicenter, Seroepidemiology Study
Ist Teil von
The Journal of infectious diseases, 2001-10, Vol.184 (8), p.1022-1028
Ort / Verlag
University of Chicago Press
Erscheinungsjahr
2001
Link zum Volltext
Quelle
Oxford Journals 2020 Medicine
Beschreibungen/Notizen
Because of the difficulty of conducting efficacy trials of vaccines against group B streptococcus (GBS), the licensure of these vaccines may have to rely on studies that measure vaccineinduced antibody levels that correlate with protection. This study estimates the level of maternal antibody required to protect neonates against early-onset disease (EOD) caused by GBS type la. Levels of maternal serum IgG GBS la antibodies, measured by ELISAs in 45 case patients (neonates with EOD caused by GBS la) and in 319 control subjects (neonates colonized by GBS la but without EOD) born at ≥34 weeks gestation were compared. The probability of developing EOD declined with increasing maternal levels of IgG GBS la antibody (P = .03). Neonates whose mothers had levels of IgG GBS la antibody ≥5 µg/mL had an 88% lower risk (95% confidence interval, 7%-98%) of developing type-specific EOD, compared with those whose mothers had levels <.5 µg/mL. A vaccine that induces IgG GBS la antibody levels <5 µg/mL in mothers can be predicted to confer a high degree of type-specific immunity to EOD to their infants.